NanoSphere Develops New Product Eliminating Need to Smoke Cannabis
DENVER–(BUSINESS WIRE)–NanoSphere
Health Sciences Inc. (CSE:NSHS) (OTC:NSHSF) is pleased to announce
the Company has developed a new intraoral delivered cannabis product for
the Canadian market, which produces similar effects to smoking cannabis,
but is safer and more effective than edibles.
Regular consumers of cannabis know the effect of cannabis when smoked is
very different than the effect when taken orally. The Evolve NanoGel™
uses NanoSphere’s patented delivery system to transport a full spectrum
of THC, other cannabinoids and terpenes through the gums and directly to
the bloodstream and into cannabinoid receptors. The result for both
medical and recreational consumers are vastly more effective products.
“Oils taken edibly go through the gut where THC is transformed by the
liver into a more psychoactive substance called 11-hydroxy-THC
(11-OH-THC),” explains Chief Science Officer Dr. Richard Clark Kaufman.
“Both have psychotropic effects, but they are quite different in the way
they affect the human brain, and many people do not tolerate 11-OH-THC
very well.”
On the other hand, Kaufman points out that smoking or vaping cannabis
may have long term adverse effects on the respiratory system.
“With the NanoSphere Delivery System™ you get a very similar effect to
smoking cannabis, but without risking damage to your lungs, and you
don’t risk an overload of 11-OH-THC as you would by taking an edible,”
he said.
NanoSphere, its affiliate NanoSphere Cannabis International (NCI) and
partner firm Delta 9 Cannabis Inc. (TSXV:NINE) (OTC:VRNDF) (“Delta 9”)
will be applying to Health Canada for approval to have the NanoGel oil
produced and sold in Canada.
“There are several issues for Canadians that this new product line can
resolve,” said NCI President Gary Symons. “Many landlords and condo
associations are now banning the smoking of cannabis, so for many
people, they literally have nowhere they can consume a legal product
without risking eviction or a lawsuit.
“Just as importantly, for medical patients, NanoSphere intraoral product
is designed to provide faster onset, greater bioavailability, and
precise dosage,” Symons added. “This product has the potential to
revolutionize cannabis therapies for a variety of medical conditions.”
NanoSphere is currently developing three primary types of delivery
system platforms for cannabis. The first is the award-winning
NanoSphere’s transdermal serum which is already being produced in
Colorado and California. The second is the Evolve NanoGel, an intraoral
product line developed for Canada and the U.S. The third is an
intranasal N2B (nose-to-brain) gel, a breakthrough product that bypasses
the blood-brain barrier to deliver a much higher proportion of THC and
cannabinoids directly to the brain, and, with a very fast onset time of
less than 90 seconds.
NanoSphere Health Sciences holds the world’s first and only patent for
nanoparticle delivery of cannabinoids through the use of a new
stabilized, clinically-proven natural lipid nanoparticle called a
‘NanoSphere’.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining
several licensing opportunities via a rigorous evaluation process. For
more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences Inc., is a biotechnology firm specializing in
the creation of the NanoSphere Delivery System™, a revolutionary
platform using nanotechnology in the biodelivery of supplements,
nutraceuticals and over-the-counter medications for the cannabis,
pharmaceutical and animal health industries, and beyond. NanoSphere
Delivery System™ represents one of the most important developments for
advancing the non-invasive and user-friendly delivery of biological
agents in over 25 years. For more information on NanoSphere, please
visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world’s first and only
scientifically proven nanoparticle delivery system in cannabis. Evolve’s
pioneering product, Transdermal NanoSerum™, is a fast-acting,
ultra-strength transdermal formula infused with nano-encapsulated
cannabis and cannabis extracts. NanoSerum™ immediately penetrates the
skin to deliver direct-focused results and intelligently carries a full
spectrum of cannabinoids and phytochemicals to receptors throughout the
body for systemic healing. Evolve Formula products leverage NanoSphere
Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere
Delivery System™ is a revolutionary platform using nanotechnology in the
biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health
industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/.
Follow us on Facebook,
Instagram
and Twitter.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Without limitation, these include assumptions, risks and uncertainties
inherent in completing sub-licensing arrangements in the United States,
Canada and abroad, product demand, production, competition and
government regulation of the Cannabis industry, any and all of which may
have an adverse effect on the Company’s expansion plans, sales, revenues
and its financial results and condition. In this release the
Company’s intention to produce and sell the Evolve NanoGel product
depends upon Health Canada approving the product for distribution in
Canada, and there is no guarantee this will happen. Readers are advised
to rely on their own evaluation of such risks and uncertainties and
should not place undue reliance on forward looking statements. Any
forward looking statements are made as of the date of this news release,
and the Company assumes no obligation to update the forward looking
statements, or to update the reasons why actual events or results could
or do differ from those projected in the forward looking statements,
whether as a result of new information, future events or otherwise.
Contacts
On behalf of the Board
David Sutton, President and COO
720.520.4283
dsutton@nanospherehealth.com
Victor Goncalves, Executive Vice President
Mobile:
204-997-5517
E-mail: vgoncalves@nanospherehealth.com
